Turnstone Biologics Azioni (NASDAQ: TSBX)

Ultime notizie per Turnstone Biologics (NASDAQ:TSBX) Azioni

Turnstone Biologics

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Turnstone Biologics Corp

Elon Musk&#8216;s dream of sending humans to Mars might receive a substantial boost following Donald Trump&#8217;s recent presidential victory. The new administration is reportedly planning to prioritize Mars missions, potentially shifting NASA&#8217;s current focus from the moon to the Red Planet.
What Happened: Sources suggest that the Trump administration may alter NASA&#8217;s Artemis program, which currently uses SpaceX&#8216;s Starship for lunar missions as a stepping stone to Mars. This shift could pave the way for uncrewed Mars missions within the decade, as per four individuals familiar with Trump&#8217;s evolving space policy, Reuters reported on Friday.
In a gesture of support, Musk attended a Trump rally wearing an &#8220;Occupy Mars&#8221; T-shirt and contributed $119 million to Trump&#8217;s campaign. Trump, who initiated the Artemis program in 2019, has expressed intentions to revamp it, aiming for a more ambitious Mars plan.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41758045/dogecoin-jumps-on-election-day-poll-asks-if-trump-or-harris-victory-will-spark-2025-rally?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Jumps On Election Day: Poll Asks If Trump Or Harris Victory Will Spark 2025 Rally</a>
SpaceX, Musk, and the Trump campaign have not yet commented on these developments. Meanwhile, NASA refrained from speculating on potential changes under the new administration. As Trump&#8217;s transition team forms, plans could still evolve, according to sources.
Why It Matters: <a href="https://www.benzinga.com/news/24/09/41080004/elon-musk-aims-for-mars-by-2030-but-experts-say-dont-count-on-it">Musk has set a target</a> for human colonization of Mars by 2030, despite skepticism from experts about the feasibility of this timeline. Musk&#8217;s plan involves launching uncrewed Starship rockets to Mars by 2026, with crewed missions potentially following two to four years later.
In a recent interview, Musk emphasized the <a href="https://www.benzinga.com/government/24/10/41621276/elon-musk-predicts-sending-starship-to-mars-in-2-years-but-warns-regulatory-hurdles-could-delay-lift">engineering success of the Starship</a> and outlined a bold timeline for sending it to Mars within two years. However, he warned that regulatory challenges could delay these plans, as obtaining launch permits often takes longer than building the rockets themselves. 
The next Mars launch window is approximately 26 to 27 months away, aligning with SpaceX&#8217;s timeline for uncrewed missions, with human missions possibly following two years later.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/11/41701075/elon-musk-warns-of-hardship-for-americans-if-trump-puts-him-in-charge-of-cutting-33-trillion-deb?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Warns Of &#8216;Hardship&#8217; For Americans If Trump Puts Him In Charge Of Cutting $33 Trillion Debt</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

News

SPACE

General

Elon Musk's Mars Ambitions Could Reportedly Get A Boost With Trump's White House Win

Piper Sandler analyst James Fish maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and raises the price target from $31 to $38.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on RingCentral, Raises Price Target to $38

WIIM

CHWY

Chewy shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $28 to $40.

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) just disclosed its Q3 earnings on Wednesday, October 30, 2024 at 04:10 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Herbalife beat estimated earnings by 63.0%, reporting an EPS of $0.57 versus an estimate of $0.35.
Revenue was down $41.00 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.13 in the last quarter, resulting in a 9.0% drop share price change the following day.
Here's a look at Herbalife's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.35</td>
<td>0.41</td>
<td>0.34</td>
<td>0.39</td>
<td>0.73</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.54</td>
<td>0.49</td>
<td>0.28</td>
<td>0.65</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.24B</td>
<td>1.33B</td>
<td>1.26B</td>
<td>1.19B</td>
<td>1.25B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.24B</td>
<td>1.28B</td>
<td>1.26B</td>
<td>1.22B</td>
<td>1.28B</td>
</tr>
</tbody>
</table>

<h3>Peer Companies' Recent Earnings</h3>
As we review Herbalife's earnings, it's important to put its results into perspective by comparing them to those of its competitors, such as Honest Co, Beauty Health, and Veru.
<ul>
<li>Honest Co, earnings revealed on August 08, 2024, exhibited robust performance this quarter. Contrary to the market's projected EPS of $-0.04, Honest Co exceeded expectations with an EPS of $-0.04, reflecting an increase of 0.0% compared to estimates. This outcome is likely to gain investor confidence</li>
<li>The latest earnings report from Beauty Health on August 08, 2024 showed a downturn in performance, with results falling short of expectations. Despite the market's EPS estimate of $-0.05, Beauty Health reported an EPS of $-0.1, marking a -100.0% decrease.</li>
<li>Veru reported earnings on August 08, 2024 that fell short of expectations, with an actual EPS of $-0.07 compared to the market's estimate of $-0.06, resulting in a -16.67% decrease.</li>
</ul>
<h3>Reviewing Competitors' Quarterly Earnings and Stock Performance</h3>
In this detailed analysis, insights are provided into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbalife</td>
<td>October 30, 2024</td>
<td style="text-align: right;">0.35</td>
<td style="text-align: right;">0.57</td>
<td>62.86%</td>
<td>$6.81</td>
<td>$7.29</td>
<td>7.05%</td>
</tr>
<tr>
<td>Honest Co</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.04</td>
<td style="text-align: right;">-0.04</td>
<td>0.0%</td>
<td>$3.24</td>
<td>$3.94</td>
<td>21.6%</td>
</tr>
<tr>
<td>Beauty Health</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.05</td>
<td style="text-align: right;">-0.10</td>
<td>-100.0%</td>
<td>$1.29</td>
<td>$1.0</td>
<td>-22.48%</td>
</tr>
<tr>
<td>Veru</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.07</td>
<td>-16.67%</td>
<td>$0.8101</td>
<td>$0.82</td>
<td>1.22%</td>
</tr>
</tbody>
</table>

<h3>Comparative Assessment: Estimated in Comparison with Actual Peer Revenues</h3>
This table presents a comparison of estimated and announced revenue figures for Herbalife's peers. It offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbalife</td>
<td>1.24B</td>
<td>1.24B</td>
<td>0.0%</td>
</tr>
<tr>
<td>Honest Co</td>
<td>87.31M</td>
<td>93.05M</td>
<td>6.57%</td>
</tr>
<tr>
<td>Beauty Health</td>
<td>99.09M</td>
<td>90.60M</td>
<td>-8.57%</td>
</tr>
<tr>
<td>Veru</td>
<td>3.50M</td>
<td>3.95M</td>
<td>12.97%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Herbalife <a href="https://www.benzinga.com/quote/HLF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Insights into Herbalife Q3 Earnings

Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) affirms Q4 sales outlook from $95.00 million-99.00 million to $95.00 million-99.00 million.

Guidance

HIPO

Hippo Holdings Affirms Q4 Sales Guidance to $95.00M-$99.00M

Piper Sandler analyst James Fish maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Overweight and raises the price target from $35 to $46.

FIVN

Piper Sandler Maintains Overweight on Five9, Raises Price Target to $46

Piper Sandler analyst James Fish maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Neutral and raises the price target from $83 to $92.

Piper Sandler Maintains Neutral on Cloudflare, Raises Price Target to $92

<a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38909768/the-dogecoin-explosion-made-something-click-in-me-veteran-trader-shares-secrets-to-turning">Pseudonymous millionaire trader</a> &#8216;Unipcs,&#8217; informally known as &#8216;BONK Guy,&#8217; has been highlighted by on-chain analytics firm Lookonchain for amassing significant gains by investing early in the Department of Government Efficiency (DOGE) and MAGA (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MAGA</a>) meme coins.
What Happened: Lookonchain on Friday <a href="https://x.com/lookonchain/status/1854831903301652639">shared</a> the trader&#8217;s journey, which saw him investing 235 Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), valued at $584,000, when <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s">the Musk-themed DOGE</a> — not to be confused with the much bigger and more popular Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) — traded at a $2.7 million market cap, yielding him 33.35 million DOGE, now worth $4.7 million. This investment currently sits at an unrealized profit of $4.12 million.
The trader also invested in the MAGA coin, a meme asset associated with Donald Trump, spending 18.45 ETH (about $57,000) to acquire 6.27 billion MAGA tokens, now valued at $452,000, yielding an unrealized profit of $395,000.
Unipcs' MAGA holdings once reached a peak unrealized profit of $4.33 million before a price pullback. True to the &#8220;diamond hands&#8221; philosophy, he has held onto his MAGA tokens, despite the volatility. His profits decreased by $3.94 million.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41803277/dogecoin-up-79-in-a-month-nears-0-20-with-beautiful-bounce-from-key-levels-analysts-say">Dogecoin Up 79% In A Month, Nears $0.20 With &#8216;Beautiful Bounce From Key Levels,&#8217; Analysts Say</a>
Why It Matters: Unipcs's experience illustrates the &#8220;diamond hands&#8221; mentality in crypto, showing the potential rewards for those who stay committed through market turbulence.
In another <a href="https://x.com/theunipcs/status/1854253375040127157">tweet</a>, Unipcs stated that the original Dogecoin could be the next meme coin to reach a $100 billion market cap, using Elon Musk's "DOGE" acronym as a symbol of the meme coin's strength.
IntoTheBlock data shows large transaction volume for Dogecoin decreased by 35.6% with active addresses down 26.3% and high-value transactions falling from 2,183 to 1,085. Net exchange flows, however, are up by 15%.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s">Elon Musk&#8217;s &#8216;DOGE&#8217; Department Mention Gives Dogecoin Boost To Top Of Daily Gainers: Memecoin Spikes 6%</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$ETH

$MAGA

Millionaire Trader Up Over $4 Million With DOGE And MAGA Coins — But The DOGE Coin Isn't What You Think It Is

Piper Sandler analyst Biren Amin maintains Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Overweight and raises the price target from $91 to $115.

ACLX

Piper Sandler Maintains Overweight on Arcellx, Raises Price Target to $115

Mineral Resources (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MALRF#OTC">MALRF</a>) faces uncertain times as founder and managing director Chris Ellison steps down amid serious governance issues.
The issue has triggered a formal investigation by the Australian Securities and Investments Commission (ASIC) and scrutiny from the Australian Taxation Office (ATO).
The probe follows allegations that Ellison evaded taxes using offshore entities and misused company resources for personal benefit. Law firm Herbert Smith Freehills engaged to review the allegations, finding multiple governance lapses within the company's leadership.
Billionaire Ellison, a prominent figure in the mining sector, will remain as a managing director until the board finds a suitable successor within the next 18 months. The board has imposed a financial penalty of $5.85 million on Ellison, alongside $6.37 million in lost remuneration.
"With the interests of shareholders absolutely front and center, the board has determined there needs to be an orderly leadership transition, significant strengthening of governance protocols, and a financial penalty imposed on Mr. Ellison," said chair James McClements <a target="_blank" href="https://www.theguardian.com/australia-news/2024/nov/04/chris-ellison-mineral-resources-boss-exit-step-down-ntwnfb" rel="noreferrer noopener">per</a> The Guardian.
ASIC's Deputy Chair, Sarah Court, confirmed <a target="_blank" href="https://www.afr.com/companies/mining/minres-directors-slammed-over-big-bonuses-to-ellison-20241107-p5kokj" rel="noreferrer noopener">for</a> AFR that an investigation is underway, noting the ATO's involvement as well. "We've now commenced a formal investigation into these issues," Court said, clarifying that the probe will assess potential breaches of laws under ASIC's jurisdiction.
Following these events, Moody's Investor Service has downgraded Mineral Resources' outlook to negative, citing potential fallout from governance challenges.
"The managing director's transition creates uncertainties around the company's strategic direction and financial policy settings," Moody's <a target="_blank" href="https://www.moodys.com/research/docid--PR_497954" rel="noreferrer noopener">stated</a>, pointing at risks that could impact the company's relations with customers, joint venture partners, and lenders.
Ellison addressed the allegations with an apology, stating, "I am deeply sorry for the events that have occurred and the impact they have had on MinRes' reputation. I apologize to the board and our people, who expect and deserve better from me."
Founded in 2006 through a merger of several resource service companies, Mineral Resources has become a diversified player in Australia's mining landscape. It operates across iron ore, natural gas, and energy solutions and holds interests in lithium projects such as the Wodgina mine.
The company has lost 45.5% of its market cap year-to-date, a decline due to falling ore and lithium prices and internal turmoil.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41769288/donald-trumps-victory-could-disrupt-commodities-put-australia-in-precarious-position" target="_blank" rel="noreferrer noopener">Donald Trump's Victory Could Disrupt Commodities, Put Australia In Precarious Position</a></li>
</ul>
Photo by RomanR for Shutterstock

Large Cap

Commodities

Legal

MALRF

Mineral Resources Confirms Founder's Departure Amid Tax Evasion Allegations, Moody's Cuts Outlook

Wells Fargo analyst Stan Berenshteyn upgrades Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from Underweight to Equal-Weight and raises the price target from $19 to $41.

Upgrades

DOCS

Wells Fargo Upgrades Doximity to Equal-Weight, Raises Price Target to $41

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $63 price target.

Reiteration

ARCT

HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $63 Price Target

Wells Fargo analyst Chris Carey upgrades Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from Underweight to Overweight and raises the price target from $52 to $74.

Wells Fargo Upgrades Molson Coors Beverage to Overweight, Raises Price Target to $74

Piper Sandler analyst Andrew Liesch assumes City Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCO#NASDAQ">CHCO</a>) with a Neutral rating and announces Price Target of $135.

Initiation

CHCO

Piper Sandler Assumes City Holding at Neutral, Announces Price Target of $135

PTC shares are trading higher. On Wednesdsay, the company reported better-than-expected Q4 financial result and issued FY24 revenue guidance above estimates

Medicine Man Technologies, Inc., operating as Schwazze (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SHWZ#OTC">SHWZ</a>) announced its preliminary financial results Thursday for the third quarter ended Sept. 30, 2024. The Colorado-based cannabis company reported revenue of approximately $42 million, which compares to revenue of $46.75 million in the same period last year.
"We continued to generate momentum from our retail growth and optimization initiatives in Q3, reflected by our ability to outpace two highly competitive markets while generating sequential improvements in profitability and positive cash flow from operations," stated Forrest Hoffmaster, Interim CEO of Schwazze. "Our efforts to sharpen our pricing and promotional strategy, elevate the in-store experience, and improve product quality, assortment and in-stock positions are yielding positive results. I'm proud of our team's hard work and dedication to drive these improvements in the overall customer experience, which has led to increased store traffic in both Colorado and New Mexico. Over the past year, our focused efforts to optimize our operations have built a solid foundation, setting the stage for sustained growth and enhanced levels of profitability in the year ahead."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41829762/cannabis-co-jushi-reports-q3-earnings-higher-margins-despite-revenue-dip-whats-driving-profitabi">Cannabis Co. Jushi Reports Q3 Earnings: Higher Margins Despite Revenue Dip – What&#8217;s Driving Profitability?</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Q3 2024 Preliminary Financial Results</h2>
Based on preliminary and unaudited results, the company expects to report the following for the third quarter ended September 30, 2024:
<ul>
<li>Adjusted EBITDA of approximately $11 million, compared to $14.12 million in the third quarter of 2023.</li>
<li>Cash flow from operations of approximately $200,000, compared to $6.95 million in the same period last year.</li>
</ul>
At quarter end, Schwazze held cash and cash equivalents of approximately $11 million, with principal amount of debt outstanding of approximately $196 million.
This compares to cash and cash equivalents of $12.3 million and total debt of $163.4 million at the end of the previous quarter (June 30, 2024). On Dec. 31, 2023, the debt amounted to $156.8 million, indicating continued growth.
<h2 class="wp-block-heading">Update On Delayed Filing</h2>
As previously announced on April 8, 2024, Schwazze dismissed BF Borgers CPA PC as its registered public accountant and engaged Baker Tilly US, LLP as its new accountant. Subsequent to the transition, on May 3, 2024, the SEC issued an order against BF Borgers for systemic failures in meeting PCAOB standards, which impacted over 1,500 SEC filings and affected at least 75% of BF Borgers' 369 clients.
As a result of the SEC order, Schwazze's new auditor needs additional time to complete its prior period review, which includes re-auditing the company's fiscal year 2023 financial statements and re-reviewing the closing of its 2022 balance sheet prior to filing its 2024 annual report. Baker Tilly is working to re-audit the company's financial statements for the associated periods.
Due to the ongoing re-review process, Schwazze anticipates a delay in filing its quarterly report on Form 10-Q for the three- and nine-months ending September 30, 2024. Moreover, the company expects to simultaneously file its quarterly report on Form 10-Q for the three months ending March 31, 2024, and June 30, 2024.
<h2 class="wp-block-heading">Price Action</h2>
Schwazze shares closed Thursday's market session flat at 15 cents per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41832358/green-thumb-grows-revenue-to-287m-in-q3-expands-cannabis-retail-network">Green Thumb Grows Revenue To $287M In Q3, Expands Cannabis Retail Network</a></li>
</ul>
Image via Shutterstock

Cannabis

SHWZ

Schwazze's Q3 Preliminary Revenue Slides As Debt Grows, 2023 Financials Face Re-Audit

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4294831-1&amp;h=3126387579&amp;u=https%3A%2F%2Fintensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc.">Intensity Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers,&nbsp;today announced that its Phase 3 trial has been selected for an oral podium presentation at the 2024 Connective Tissue Oncology Society (CTOS) on November 16, 2024. Dr. Christian F. Meyer MD, Ph.D will be making the oral presentation highlighting completed Phase 2 results and the INVINCIBLE-3 (Phase 3) randomized soft tissue sarcoma trial design and important study criteria. The annual CTOS conference runs from November 13 to 16, 2024 in San Diego at the Grand Hyatt.

Biotech

INTS

Intensity Therapeutics Selected For Oral Podium Presentation In A Late-Breaking Session At The 2024 Annual Connective Tissue Oncology Society Meeting

Piper Sandler analyst Andrew Liesch assumes Community Trust Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTBI#NASDAQ">CTBI</a>) with a Overweight rating and announces Price Target of $64.

CTBI

Piper Sandler Assumes Community Trust Bancorp at Overweight, Announces Price Target of $64

Daktronics, Inc. ("Daktronics" or the "Company") (NASDAQ-DAKT), the leading U.S.-based designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide, today announced that, after careful deliberation, the Board of Directors (the "Board") has determined that it is in the best interests of the Company and its common shareholders to exercise the Company's right to convert an initial $7.0 million in face value of the $25 million senior second lien secured promissory note (the "Convertible Note") held by Alta Fox Capital Management, LLC (together with its affiliates, "Alta Fox") into approximately 1.1 million shares of the Company's common stock. &nbsp;
The Board intends to deliver to Alta Fox notice of the conversion on November 11, 2024, with a conversion date of December 3, 2024. The Company intends to convert the remainder of the Convertible Note over the next several months, in tranches of up to $7 million in face value every 30 days, as provided for in the Convertible Note.
Daktronics has delivered outstanding financial results over the last twelve months, with record revenue, gross profit and operating income in fiscal year 2024, and strong returns for shareholders, with the Company's stock price increasing more than 300% over the last two years and over 175% since the issuance of the Convertible Note on May 11, 2023.1 This performance is the result of several initiatives implemented by the management team and Board, including strengthening the Company's financial position, reducing order backlog, and improving margins through operational enhancements and strategic cost reductions.
The Board's decision to force the conversion of the Convertible Note is consistent with the Company's ongoing focus on balance sheet optimization and cost efficiency and will save the Company approximately $5.4 million in interest expense over the remaining term of the Convertible Note. To help offset the share dilution that will result from the conversion of the Convertible Note into common stock, the Company intends to execute on its existing share repurchase authorization as soon as practicable.

Financing

DAKT

Daktronics Announces Intention To Convert $25M Convertible Promissory Note Into Common Stock

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $30 price target.

CPRX

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $30 Price Target

In a report released yesterday, Daina Graybosch from Leerink Partners maintained a Hold rating on Turnstone Biologics Corp. (TSBX – Research Report...

Turnstone Biologics Corp. (TSBX) Gets a Hold from Leerink Partners

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lexicon Pharmaceuticals (LXRX – Research Report) a...

Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Turnstone Biologics Corp. (TSBX)

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Turnstone Biologics Corp. (TSBX – Research Report), with...

Piper Sandler Remains a Buy on Turnstone Biologics Corp. (TSBX)

Turnstone Biologics Corp. ( ($TSBX) ) has shared an announcement. Turnstone Biologics Corp. has initiated a strategic reorganization to hone its fo...

Turnstone Biologics Streamlines Operations and Leadership

Warning: TSBX is at high risk of performing badly

Turnstone Biologics (TSBX) announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society fo...

Turnstone Biologics presents two posters on methods for TIL selection at SITC

LXRX

TSBX

Management

Press Releases

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

Turnstone Biologics to Participate in Upcoming Investor Conferences

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Appoints William Waddill to its Board of Directors

Health Care

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Comments

Turnstone Biologics

Notizie

Ultime notizie per Turnstone Biologics (NASDAQ:TSBX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO